EBIM
BIO icon

Eagle Boston Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Eagle Boston Investment Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-825
Closed -$206K – 156
2018
Q1 		$206K Buy
+825
New +$210K 0.02% 148

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Eagle Boston Investment Management's BIO Position: Q2 2018 in Review

Eagle Boston Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2018, closing a stake of 825 shares — an estimated $206K sold.

Eagle Boston Investment Management first reported a position in BIO in Q1 2018 and held it in 1 quarter. The position peaked at $206K in Q1 2018. 326 funds tracked by Wall St. Rank hold BIO as of Q2 2018.

  • Eagle Boston Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2018 after selling out during the quarter.
  • Eagle Boston Investment Management sold 825 Bio-Rad Laboratories Class A shares in Q2 2018, an estimated $206K.
  • Eagle Boston Investment Management first reported a position in Bio-Rad Laboratories Class A in Q1 2018 and held it in 1 quarter.
  • Eagle Boston Investment Management's Bio-Rad Laboratories Class A position peaked at $206K in Q1 2018.
  • 326 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2018.

Based on Eagle Boston Investment Management's 13F filing for Q2 2018, filed 7 Aug 2018.